Characterization of the latent membrane protein 1 signaling complex of Epstein-Barr virus in the membrane of mammalian cells with bimolecular fluorescence complementation by Talaty, Pooja et al.
RESEARCH Open Access
Characterization of the latent membrane protein
1 signaling complex of Epstein-Barr virus in the
membrane of mammalian cells with bimolecular
fluorescence complementation
Pooja Talaty, Amanda Emery and David N Everly Jr
*
Abstract
Background: Bimolecular fluorescence complementation (BiFC) is a novel technique to examine protein-protein
interaction through the assembly of fluorescent proteins. In the present study, BiFC was used to study the
assembly of the Epstein-Barr virus latent membrane protein 1 (LMP1) signaling complex within the membrane of
mammalian cells. LMP1 signaling requires oligomerization, localization to lipid rafts, and association of the
cytoplasmic domain to adaptor proteins, such as the tumor necrosis factor receptor associated factors (TRAFs).
Methods: LMP1-TRAF and LMP1-LMP1 interactions were assayed by BiFC using fluorescence microscopy and flow
cytometry. Function of LMP1 BiFC contructs were confirmed by transformation assays and nuclear factor- B (NF-
B) reporter assays.
Results: BiFC was observed between LMP1 and TRAF2 or TRAF3 and mutation of the LMP1 signaling domains
reduced complementation. Fluorescence was observed in previously described LMP1 signaling locations.
Oligomerization of LMP1 with itself induced complementation and BiFC. LMP1-BiFC constructs were fully functional
in rodent fibroblast transformation assays and activation of NF-B reporter activity. The BiFC domain partially
suppressed some LMP1 mutant phenotypes.
Conclusions: Together these data suggest that BiFC is a unique and novel platform to identify and characterize
proteins recruited to the LMP1-signaling complex.
Keywords: Epstein-Barr Virus, latent membrane protein 1, bimolecular fluorescence complementation, TRAF2,
TRAF3
Background
Epstein-Barr virus (EBV) is a DNA tumor virus that
latently infects and immortalizes B-lymphocytes. The
latent membrane proteins of EBV induce constitutive
signaling to establish latency and ensure the survival of
the infected cell [1,2]. Latent membrane protein 1
( L M P 1 )o fE B Vi st e r m e dt h eE B Vo n c o g e n ea si ti s
required for EBV B-cell transformation and sufficient to
transform rodent fibroblasts [3-9]. LMP1 expression is
also frequently detected in the cancers associated with
EBV [1,2,10-12]. It alters the cellular environment by
inducing a number of signaling pathways, including
nuclear factor-  B( N F - B), phosphoinositide 3-kinase
(PI3K), mitogen-activated protein kinase, and c-Jun N-
terminal kinase [6,7,13-19].
LMP1 has a short cytoplasmic amino terminus, a six
pass transmembrane domain, and a cytoplasmic car-
boxyl-terminal signaling domain. The transmembrane
domain is required for ligand-independent self-associa-
tion and localization to lipid raft domains of the mem-
brane [20-26]. Mutations in the membrane domain that
impair LMP1 raft localization can block signaling
[22,27-29]. LMP1 signaling is initiated by binding of
adaptor proteins to the two carboxyl-terminal activating
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tumor necrosis factor receptor-associated factors
(TRAF)1, TRAF2, TRAF3, and TRAF5 [30]. CTAR2
binds other adaptors, including TNFR-associated death
domain and receptor interacting protein 1, that in turn
recruit TRAF2 and TRAF6 [15,31]. Interferon regulatory
factor 7 is also recruited to CTAR2 and is activated by
TRAF6-dependent ubiquitylation [32-34]. Although it is
clear that LMP1 signaling requires the TRAFs and other
adaptor proteins, downstream proteins recruited to the
LMP1 signaling complex continue to be defined.
The CTAR1 domain is critical for activation of dis-
crete signaling pathways and cellular phenotypes. Acti-
vation of PI3K and extracellular-signal-regulated kinase
(ERK) signaling through CTAR1 correlates with fibro-
blast transformation and epithelial cell motility and
invasion [5-7,35-37]. Inhibition of PI3K or ERK signaling
blocks these effects. Activation of PI3K signaling is cor-
related with regulation of several proteins important for
promoting cell cycle progression [5-7]. LMP1 downregu-
lates p27KIP1 transcriptionally through the effects of a
repressive E2F complex, E2F4/p130 [38]. Several other
pathways have recently been associated with CTAR1
ERK activation, including STAT3, PKC(delta), and non-
canonical NF-B (p50/p50/Bcl3 complexes) [39-42]. The
exact mechanisms of LMP1-induced signaling through
CTAR1 to induce transformation and cell cycle have
not been fully elucidated.
Understanding the dynamic molecular events within
the membrane resulting in LMP1 signaling is a complex
and difficult biological problem. In recent years a num-
ber of enzyme and fluorescence based complementation
assay have been developed that can be applied to mem-
brane proteins [43]. In bimolecular fluorescence comple-
mentation (BiFC) interacting proteins are expressed as
fusion proteins with fragments of yellow fluorescence
protein (YFP) [44]. Individually proteins do not possess
intrinsic fluorescence but interaction between proteins
leads to assembly of functional YFP which can be
detected by fluorescence based techniques, such as
fluorescence microscopy and flow cytometry.
The goal of the current study was to examine the
assembly of the LMP1 signaling complex using BiFC.
Fluorescence complementation was observed for LMP1
with TRAF2, LMP1 with TRAF3, and LMP1 with itself.
Fluorescence was localized to perinuclear and mem-
brane regions of the cell which is consistent with pre-
viously described localization of LMP1 signaling
complexes. Mutations in CTAR1 and CTAR2 decreased
the complementation of LMP1 with the TRAFs. LMP1
containing the YFP domain was fully functional in
rodent fibroblast transformation and in the induction of
NF-B reporter plasmids. These results suggest that
BiFC is an attractive way to analyze the assembly of
signaling complexes with full-length LMP1 protein and
to understand the contribution of the membrane por-
tion of LMP1 to signaling.
Methods
Plasmids
BiFC plasmids encoding Venus YFP fusion proteins
were constructed by Stephen W. Michnick (University
of Montreal, Montreal, Quebec, Canada [45]). The plas-
mids contain the leucine zipper domain (zip) of the
yeast protein, general control nondepressible 4, fused at
the amino or carboxyl termini to the amino (NYFP) or
carboxyl (CYFP) fragment of Venus YFP. The zip
domain is fused at either end of each YFP fragment,
zip-NYFP, zip-CYFP, NYFP-zip, and CYFP-zip. The zip
and YFP coding sequences are flanked by unique restric-
tion enzyme sites and separated by a sequence encoding
a 10 amino acid linker (GGGGSGGGGS). LMP1 and
TRAF sequences were cloned by PCR using primers
containing the appropriate restriction enzymes to
replace the zip domain and maintain proper coding
frame with the YFP sequences. All constructs described
below were completely sequenced to confirm the desired
clones.
LMP1-binding TRAF2 and TRAF3 constructs have
been previously described [7]. TRAF2 (amino acids 98-
501, NM_021138) and TRAF3 (amino acids 345-568,
NM_003300) contain the LMP1-binding TRAF domain
but lack RING (really interesting new gene) and zinc
finger domains. Constructs with CYFP at the C-termi-
nus of the myc-tagged TRAFs were cloned with CYFP
to create TRAF2-CYFP and TRAF3-CYFP. Fusions at
the N-terminus of the TRAFs were cloned to create
CYFP-TRAF2 and CYFP-TRAF3. N-terminally tagged
TRAFs lack the myc-epitope tag.
Full-length LMP1 from B95-8 strain EBV (K02165)
was cloned with NYFP and CYFP in various orienta-
tions. Previously characterized LMP1 mutants impaired
in LMP1 signaling were also cloned into BiFC vectors
[5-7]. Mutants include LMP1-A5 (A5) which contains
CTAR1 mutations (amino acids 204-208 PQQAT
mutated to AAAAA). LMP1-Y384G (Y384G) contains a
CTAR2 point mutation (Y 384 to G) that abrogates
CTAR2 signaling [46,47]. A5-Y384G contains point
mutations in both CTAR1 and CTAR2. 1-231 contain-
ing amino acids 1 through 231 is deleted for CTAR2
but contains CTAR1, while 1-231-A5 is deleted for
CTAR2 and contains the A5 mutations in CTAR1. The
1-187 mutant is deleted for both CTAR1 and CTAR2
and contains only the transmembrane domain. The
mutant CTAR1/2 contains only the cytoplasmic signal-
ing domain of LMP1 from amino acids 184 to 386 and
lacks the membrane domain. The expression vector
pmCherry-N1 encoding the red fluorescent protein,
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expression cassette encoding LMP1-NYFP was sub-
cloned into retrovirus packaging vector pBabe-puro for
use in transformation assays.
Cell Culture, Transfections, and Retrovirus
Human embryonic kidney-293T (HEK-293T) and Rat-1,
rodent fibroblasts, cells were maintained in Dulbecco
modified Eagle medium (Mediatech) supplemented with
antibiotic/antimycotic mixture and 10% (v/v) heat-inac-
tivated fetal bovine serum. Cells were transfected with
Transit-LT1 (Mirus) according to the manufacturer’s
directions. Retrovirus production was accomplished as
previously described [38] by transfection of HEK-293T
cells with control (Babe-puro), LMP1, or LMP1-NYFP
packaging vectors with plasmids expressing vesicular
stomatitis virus G protein and gag-pol from Moloney
murine leukemia virus. Twenty-four hours post-trans-
fection media was changed and cells were moved to 33°
C. Fourty-eight hours post-transfection clarified super-
natents were collected and used to infect Rat-1 cells.
Retrovirus infection was performed in the presence of 8
μg/ml polybrene. Stably transduced Rat-1 cells were
selected with puromycin (5 μg/ml, Mediatech).
Western blotting
Cells were washed with ice cold phosphate buffered sal-
ine (PBS, Mediatech) and lysed with radio immunopre-
cipitation assay buffer (10 mM Tris-HCl, pH 8.0, 140
mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sul-
fate (SDS), 1% deoxycholic acid, protease and phospha-
tase inhibitors (Pierce)). Cell lysates were clarified by
centrifugation and quantitated by Bio-Rad DC protein
assay system (Bio-Rad). Samples were then boiled in
SDS sample buffer and indicated amounts of protein
were separated using SDS-polyacrylamide gel electro-
phoresis, and transferred to nitrocellulose membranes
(LiCor) for western blotting analysis. LMP1 was detected
with a mixture of four rat monoclonal antibodies diluted
1 : 5 0 0e a c h( C a o7 E 1 0 ,C a o8 G 3 ,L M P 1I G 6 ,a n dC a o
7G8, Ascenion GmbH). TRAF2 and TRAF3 antibodies
were purchased from Santa Cruz. Fusion proteins were
detected with myc-tag antibody (Upstate) and YFP anti-
bodies (632460 polyclonal for NYFP and CYFP and
632381 monoclonal for CYFP from Clontech). Primary
antibodies were detected with IRDye™ labeled second-
ary antibodies (Li-Cor) and scanning with a Li-Cor
Odyssey imaging system. Bands were quantitated using
the Li-Cor imaging software.
BiFC Assays
Different combinations of BiFC plasmids were trans-
fected into HEK-293T cells and examined by fluores-
cence techniques. For fluorescent microscopy, cells were
plated on coverslips and fixed 24 hours post-transfection
with 4% paraformaldehyde in PBS for ten minutes at
room temperature and washed with PBS. Coverslips
were mounted with ProLong Gold Antifade reagent con-
taining 4’-6-Diamidino-2-phenylindole (DAPI, Invitro-
gen). Cells were examined at low magnification for YFP
fluorescence. High resolution images were acquired
using the Olympus Fluoview 300 confocal microscope at
the microscopy core of Rosalind Franklin University of
Medicine and Science (RFUMS) at 60 × objective under
oil immersion. Analysis was performed using Fluoview
software (Olympus, Melville, NY).
Cells used for flow cytometry were co-transfected with
pmCherry-N1 (Clontech) to enrich for transfected cells.
Forty-eight hours post-tranfection cells were trypsinized,
washed, and resuspended in PBS. Fluorescence was
determined using the LSRII Flow Cytometer (BD Bios-
ciences) in the Flow Cytometry Core Facilty of RFUMS.
The main cell population was gated using the forward
scatter versus side scatter dot plot. Transfected cells
were enriched by gating for mCherry fluorescent cells.
YFP gating was determined by comparing the histo-
grams of mCherry alone transfected cells with BiFC
plasmid transfected cells. 1 × 10
4 mCherry positive cells
were analyzed for each combination of plasmids and the
mean fluorescent intensity (MFI) of YFP was deter-
mined. Flow cytometry data was analyzed with BD
FACSDiva (BD Biosciences) and FlowJo (Tree Star) soft-
ware. Cells were also harvested for western blotting to
confirm expression of BiFC plasmids.
Reporter Assays
Reporter assays were performed as previously described
[38]. HEK-293T cells were plated 1:5 into 12-well plates
one day prior to transfection. Cells were transfected
with 0.2 μg of pRL-SV40 (Renilla luciferase) (Promega),
0.2 μgo fp N F - B-Luc (Stratagene), and 0.2 μg of vector
or LMP1-expressing plasmids. Forty hours post-transfec-
tion cells were harvested and luciferase activity was
assayed using the Dual-Luciferase
® Reporter Assay Sys-
tem (Promega) according to the manufacturer’s direc-
tions. Relative luciferase activity was determined by
dividing the firefly luciferase activity of the NF-Bp r o -
moter constructs by the internal control Renilla lucifer-
ase activity. Each condition was done in triplicate and
replicated in at least three experiments.
Transformation Assays
Transformation assays were performed as previously
described [6]. Focus formation assays were performed
by infection of subconfluent monolayers of Rat-1 cells
followed by growth for 10 days to allow for focus forma-
tion. Foci were fixed and stained with 1% (w/v) crystal
violet in 50% (v/v) ethanol. For colony formation assays
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5×1 0
5/well. Colonies were grown for 10 days and
stained with MTT (methylthiazolyldiphenyl-tetrazolium
bromide, Sigma) for one hour. Subconfluent stable cells
were stained with crystal violet as above and observed
for transformed phenotype. Cellular phenotypes were
observed and documented using a Leica EZ4D dissect-
ing microscope with integrated digital camera.
Results
BiFC with the LMP1 cytoplasmic domain and TRAFs
Binding between LMP1 and the TRAFs was previously
identified using the cytoplasmic domain of LMP1 in
yeast two-hybrid (Y2H) screens [48]. To determine if
LMP1 + TRAF2 or TRAF3 binding induces fluorescence
complementation, BiFC assays were performed. LMP1,
TRAF2, and TRAF3 were cloned into BiFC expression
plasmids as fusion proteins with the amino-terminus of
YFP (NYFP) or the carboxyl-terminus of YFP (CYFP).
Constructs are named for the protein and YFP domain
that they contain in the order in which they are
encoded. NYFP-CTAR1/2 contains the amino-terminus
of YFP fused to the cytoplasmic domain of LMP1
(amino acids 184-386, containing CTAR1 and CTAR2).
TRAF2 and TRAF3 fusion proteins with CYFP at the
amino-termini, CYFP-TRAF2 and CYFP-TRAF3, were
tested. TRAFs contain several conserved domains,
including Zn-RING, Zn-fingers, TRAF-N and TRAF-C
domains. The TRAF-N and TRAF-C domains bind the
signaling domains of LMP1 and other proteins. The
zinc-binding domains also mediate protein-protein
interaction and can function as E3 ubiquitin ligases.
Since the TRAFs function as E3-ubiquitin ligases that
induce signaling and sometimes turnover [49,50], pre-
viously described truncated TRAFs that lack the E3-ubi-
quitin ligase domain but maintain the TRAF-N and
TRAF-C LMP1-binding domains were used [7].
Although these TRAFs function as dominant negatives
in the activation of downstream signaling, they maintain
LMP1-binding but avoid possible complications in sub-
sequent experiments related to their ubiquitin ligase
activity.
BiFC was determined between NYFP-CTAR1/2 and
TRAF fusion proteins by co-transfection into HEK-293T
cells and fluorescence microscopy individually or in
combination (Figure 1). Fluorescence was not observed
in cells transfected with individual plasmids in combina-
tion with empty vector plasmid (Figure 1A, B, C, and
D). Combinations of the LMP1 cytoplasmic domain
with the TRAFs induced strong fluorescence (Figure 1E
and 1F). The fluorescence was punctuate throughout
t h ec y t o p l a s ma n de x c l u d e df r o mt h en u c l e i( F i g u r e
1G). Similar results were obtained with TRAFs tagged at
their carboxyl-termini (data not shown).
In parallel, transfected cells were harvested for western
blotting (Figure 1H). Blotting with LMP1 specific anti-
body confirmed expression of NYFP-CTAR1/2 at about
50 kilodaltons (kDa) in lanes 2, 5, and 6. Strong bands
at 50 and 30 kDa bound with a monoclonal GFP anti-
body, which only reacts with CYFP. Bands of 50 and 30
kDa are consistent with predicted size of CYFP-TRAF2
(lane 3 and 5) and CYFP-TRAF3 (lane 4 and 6), respec-
tively. Much fainter bands were also observed in LMP1
and GFP blots at the appropriate molecular weights for
the transfected constructs. These bands are likely the
result of a small amount of spillover between lanes and
LMP1
TRAF2
TRAF3
GFP
monoclonal
56 1234
H) G)
D) E) F)
A) C) B) NYFP-CTAR1/2
Vector
NYFP-CTAR1/2
CYFP-TRAF2
NYFP-CTAR1/2
CYFP-TRAF3
Vector
Vector
Vector
CYFP-TRAF3
Vector
CYFP-TRAF2
-37
-50
NYFP-CTAR1/2 + CYFP-TRAF2
Figure 1 BiFC with LMP1 cytoplasmic domain and TRAFs. HEK-
293T cells were transfected with the indicated LMP1 + TRAF pairs
and transfection control, pmCherry. NYFP-CTAR1/2 expresses the N-
terminus of YFP (NYFP) fused to the cytoplasmic domain of LMP1,
amino acids 184-386, at the N-terminus. CYFP-TRAF2 and CYFP-
TRAF3 express the CYFP fused to TRAF2 and TRAF3, respectively, at
their N-termini. Twenty-four hours post-transfection cells were fixed
and examined by fluorescence microscopy for transfection (mCherry
expression) in the red panels and fluorescence complementation in
the green panels (panels A, B, C, D, E, and F). Representative phase
contrast and fluorescence micrographs are shown. High resolution
image of NYFP-CTAR1/2 + CYFP-TRAF2 cells were counter stained
with DAPI and acquired using a confocal microscope (panel G). In
parallel, cells were assayed fourty-eight hours post-transfection by
western blotting for protein expression. Lysates were blotted with
GFP monoclonal (recognizes the CYFP domain), LMP1, TRAF2, and
TRAF3 antibodies (panel H). Lanes 1-6 correspond to the
combinations in panels A-F, respectively. Locations of molecular
weight markers are indicated. Fifty micrograms of protein were
loaded in each lane.
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with TRAF2 and TRAF3 antibodies confirmed the iden-
tity of the TRAF2 and TRAF3 fusion proteins (Figure
1 H ,l a n e s3a n d5( T R A F 2 ) ,a n d4a n d6( T R A F 3 ) ) .
These data demonstrate BiFC between the cytoplasmic
domain of LMP1 with TRAF2 and TRAF3 tagged with
NYFP and CYFP, respectively, and that the complemen-
tation occurred regardless of position of the CYFP
domain relative to the TRAFs.
BiFC between full-length LMP1 and the TRAFs
Compared to traditional Y2H which requires nuclear
localization, BiFC does not require nuclear localization
and can be applied to membrane proteins [43]. Full-
length LMP1 and TRAF2 and TRAF3 in various combi-
nations were tested for BiFC (Figure 2). Because differ-
ent combinations and configurations of fusion proteins
may be required to obtain BiFC, cells were transfected
with TRAFs tagged at the amino-terminus or carboxyl-
terminus with the CYFP domain. To quantitate the rela-
tive fluorescence intensity of the different BiFC combi-
nations flow cytometry was performed. Cells were
transfected with the BiFC plasmids along with a plasmid
expressing the mCherry protein (Figure 2A). Cells were
harvested and transfected cells were analyzed by flow
cytometry by gating the main cell population followed
by cells with red fluorescence, i.e. mCherry positive
cells. YFP fluorescence intensity was determined for 1 ×
10
4 mCherry positive cells. The MFI of at least three
replicates for each combination were averaged and
plotted in Figure 2A.
Fluorescence levels were generally correlated with the
whether LMP1 or TRAFs were tagged at their carboxyl-
or amino-termini with the YFP domains. Brighter fluor-
escence was observed with the TRAFs tagged at the
amino-terminus with CYFP, LMP1-NYFP + CYFP-
TRAF2 and CYFP-TRAF3 (Figure 2A, black and white
bars, respectively), compared to LMP1-NYFP + TRAF2-
CYFP and TRAF3-CYFP (Figure 2A, gray bars). LMP1
tagged at the carboxyl-terminus with NYFP (LMP1-
NYFP) had more than 10-fold greater fluorescence than
LMP1 fusion proteins with the YFP domain at amino-
terminus of LMP1 (data not shown). LMP1-NYFP +
CYFP-TRAF2 or CYFP-TRAF3 are the combinations
that induced the greatest fluorescence.
Decreased fluorescence complementation could be the
result of steric interference with YFP domain association
or could be due to differences in the expression of the
different constructs. Expression levels of BiFC proteins
were determined by western blotting for BiFC proteins
(Figure 2B). Expression of fusion proteins was not corre-
lated with their fluorescence. LMP1-NYFP expression
was slightly increased in combination with TRAF2-
Mean fluorescence intensity
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Figure 2 BiFC between full-length LMP1 and the TRAFs.H E K -
293T cells were transfected with the indicated LMP1 + TRAF pairs.
LMP1-NYFP expresses LMP1 fused to NYFP at the C-terminus of
LMP1. The structure of LMP1 mutant and truncated constructs are
indicated, including transmembrane domain (hatched box), CTAR1
(PxQxT), CTAR2 (YYD), mutant CTAR1 (gray AAAAA), mutant CTAR2
(gray GYD), and NYFP. A5-Y384G is a full-length mutant containing
mutations in CTAR1 and CTAR2, 1-231 and 1-231-A5 are truncation
mutants that are deleted for CTAR2 with wild-type or mutant
CTAR1, respectively, and 1-187 expresses only the transmembrane
domain of LMP1 fused to NYFP. CYFP-TRAF2 and CYFP-TRAF3
express the CYFP at the amino-terminus of the TRAFs and TRAF2-
CYFP and TRAF3-CYFP express CYFP at the carboxyl-terminus of the
TRAFs. Fluorescence was quantitated by flow cytometry. BiFC
constructs were co-transfected with a mCherry expressing plasmid
and after 48 hours, cells were trypsinized, washed, and resuspended
in PBS. Cells were analyzed for mCherry and YFP fluorescence by
flow cytometry. The main cell population was gated using the
forward scatter versus side scatter dot plot and transfected cells
were enriched by gating for mCherry fluorescent cells. For each
combination, the mean fluorescent intensity (MFI) of YFP
fluorescence for 1 × 10
4 mCherry positive cells was determined
(panel A). MFI was determined in at least three independent
experiments and error bars represent the standard deviation from
the mean. In parallel protein expression was confirmed by western
blotting for LMP1 and TRAF2 constructs (panel B). TRAF2-CYFP (T2-
C) and CYFP-TRAF2 (C-T2) are recognized by a GFP monoclonal that
binds CYFP. TRAF2-CYFP contains a tandem triple-myc tag that
increases its molecular weight. LMP1 constructs were recognized
with LMP1 and GFP polyclonal antibody that recognizes the NYFP
domain.
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NYFP T2-C and C-T2, respectively). Similarly, expres-
sion of TRAF2-CYFP was slightly greater than CYFP-
TRAF2. Similar expression patterns were observed for
TRAF3 combinations (data not shown). Because expres-
sion of BiFC constructs was not correlated to their
fluorescence, this suggests that the differences in BiFC
are a result of steric interference with BiFC assembly
rather than a result of the construct expression.
Decreased BiFC with LMP1 Signaling Mutants
LMP1 point mutants were tested for fluorescence com-
plementation with TRAF2 and TRAF3 and quantitated
using flow cytometry (Figure 2A). Full-length mutant
A5-Y384G contains alanine substitutions in the PxQxT
motif of CTAR1 and a tyrosine to glycine substitution
in CTAR2. LMP1-NYFP and A5-Y384G-NYFP were
tested with TRAF2 and TRAF3 tagged at the amino-ter-
minus with CYFP (Figure 2A, white and black bars,
respectively). TRAF2 is known to bind both CTAR1 and
CTAR2 during LMP1-mediated signaling. Fluorescence
with CYFP-TRAF2 (Figure 2A, white bars) was reduced
by mutation of both CTAR1 and CTAR2 (A5-Y384G).
TRAF3 only binds to CTAR1 but not CTAR2. CYFP-
TRAF3 fluorescence was also reduced by A5-Y384G
(Figure 2A, black bars). Western blotting for LMP1 and
TRAF2 constructs indicates that LMP1 and A5-Y384G
and CYFP-TRAF2 constructs were equally expressed
and that the decrease in fluorescence was not due to
lower protein expression (Figure 2B). Similar expression
levels were observed for TRAF3 constructs (data not
shown). Although there was about a 50% decrease in
fluorescence with A5-Y384G compared to wild-type
LMP1, it was surprising that mutation of CTAR1 and
CTAR2 did not completely abolish BiFC with LMP1
and TRAFs.
In order to further characterize BiFC between LMP1
and the TRAFs, LMP1 deletions that lack CTAR2 but
containing CTAR1 (1-231), containing CTAR1 muta-
tions (1-231-A5), or deleted for the entire cytoplasmic
domain (1-187) were also tested with CYFP-TRAF2 and
CYFP-TRAF3 for BiFC (Figure 2A). 1-231-NYFP fluor-
escence with CYFP-TRAF2 and CYFP-TRAF3 was lower
than both LMP1-NYFP and A5-Y384G-NYFP combina-
tions. Mutation of CTAR1 from 1-231 to 1-231-A5
reduced the fluorescence by about one half. The mutant
containing only the transmembrane domain (1-187) had
only minimal fluorescence. Western blotting for the
truncated LMP1 mutants indicates that 1-231 is
expressed at higher levels than full-length LMP1. Since
LMP1 antibody does not recognize the transmembrane
only mutant, blotting with the GFP polyclonal antibody
that recognizes NYFP indicates that 1-187 is expressed
at a lower level than full-length or 1-231 constructs.
Because 1-187 was expressed at lower levels than the 1-
231 constructs, it is unclear if reduced fluorescence was
due to lower BiFC or impaired 1-187 expression.
Greater expression of 1-231-NYFP compared to LMP1-
NYFP did not result greater BiFC, indicating that greater
expression alone does not induce greater BiFC.
Decreased BiFC with 1-231-NYFP is likely due to steric
hindrance of YFP domain association. The fact that
fluorescence induced with the CYFP-TRAF2 and CYFP-
TRAF3 with LMP1-NYFP and 1-231-NYFP was reduced
by mutation or deletion of LMP1 signaling domains sug-
gests that the BiFC of these combinations represents
LMP1-signaling complexes. As with full-length LMP1-
NYFP + CYFP-TRAF BiFC, 1-231-A5 that should have
no TRAF binding still had greater fluorescence than 1-
187-NYFP. It is possible that overexpression of BiFC
plasmids in transient transfections may induce nonspeci-
fic BiFC.
To determine if C-terminally tagged TRAFs also
induce BiFC, BiFC of LMP1-NYFP + TRAF2-CYFP and
TRAF3-CYFP were performed (Figure 2A). BiFC was
induced between LMP1-NYFP and TRAF-CYFP con-
structs (Figure 2A, gray bars). However, BiFC was not
reduced by mutation of CTAR1 and CTAR2 with A5-
Y384G compared to LMP1 (Figure 2A, gray bars). Simi-
larly, LMP1 deletions lacking CTAR2 containing
CTAR1 (1-231), containing CTAR1 mutations (1-231-
A5), or deleted for the entire cytoplasmic domain (1-
187) with TRAF2-CYFP or TRAF3-CYFP had low fluor-
escence that was not altered by mutation or deletion of
CTAR1. Expression of TRAF2-CYFP and TRAF3-CYFP
were confirmed (Figure 2B and data not shown, respec-
tively). TRAF2-CYFP and TRAF3-CYFP contain a tan-
dem triple-myc tag that increases their molecular
weight. Since fluorescence was not reduced by CTAR1
and CTAR2 mutation or deletion, fluorescence resulting
from these combinations does not likely represent
LMP1-signaling complexes and may represent nonspeci-
fic binding.
To determine if overexpression of BiFC proteins con-
tribute to non-specific fluorescence, BiFC assays were
performed with the same amount of mCherry tracer
plasmid but ten-fold less BiFC plasmids. The YFP histo-
grams of 1 × 10
4 mCherry positive cells from BiFC
assays with lower BiFC plasmids are depicted in Figure
3A and 3B. As opposed to initial BiFC assays where
greater than 90% of mCherry cells were also YFP posi-
tive (data not shown), approximately 50% or fewer of
the mCherry positive cells were also YFP positive (Fig-
ure 3C). The YFP-positive population was gated as indi-
cated and expanded in the lower panels (Figure 3A and
3B). CYFP-TRAF2 which should be able to bind both
CTAR1 and CTAR2 induced strong fluorescence with
LMP1-NYFP (Figure 3A, blue histogram) that was
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Figure 3 BiFC Specificity with Decreased BiFC Construct Expression. LMP1-NYFP and LMP1-NYFP mutants were transfected with CYFP-
TRAF2 and CYFP-TRAF3 (Panel A and B, respectively) as in Figure 2 except that ten-fold less BiFC plasmids were used. Cells were analyzed for
BiFC by flow cytometry as in Figure 2. Representative YFP histograms of 1 × 10
4 mCherry positive cells are depicted. The YFP positive cells were
gated as indicated and expanded in the lower panels. Histograms for LMP1-NYFP (blue), A5-Y384G-NYFP (orange), 1-231-NYFP (purple), 1-231-A5-
NYFP (light green), 1-187-NYFP (dark green), and mCherry alone (no BiFC plasmids, red) are displayed. Percent YFP positive cells in the mCherry
positive population is displayed in panel C.
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Page 7 of 15decreased by mutations in CTAR1 and CTAR2 (A5-
Y384G) and deletion of CTAR2 (1-231) (Figure 3A,
orange and purple histograms, respectively). 1-231-A5
and 1-187 had virtually no YFP positive cell (Figure 3A,
green histograms) which was similar to cells transfected
with mCherry alone (Figure 3A, red histogram).
Strong BiFC was also observed with CYFP-TRAF3 +
LMP1-NYFP (Figure 3B, blue histogram). TRAF3 does
n o tb i n dt oC T A R 2a n dC T A R 2 - d e l e t e d1 - 2 3 1 - N Y F P
induces BiFC similar to LMP1-NYFP (Figure 3B, com-
pare blue and purple histograms). A5-Y384G which is
mutated for both signaling domains has decreased BiFC
(Figure 3B, orange histogram) but still has fluorescence
greater than the other mutants which should not bind
TRAF3, 1-231-A5 and 1-187 (Figure 3B, green histo-
grams). Transfection of less BiFC plasmids seems to
recapitulate TRAF-LMP1 binding. TRAF2 can bind to
b o t hC T A R 1a n dC T A R 2a n df u l l - l e n g t hL M P 1 - N Y F P
has greater fluorescence than 1-231-NYFP which is
deleted for CTAR2 with CYFP-TRAF2. TRAF3 only
binds to CTAR1 and LMP1-NYFP and 1-231-NYFP
have similar fluorescence with CYFP-TRAF3. A5-Y384G
which is predicted to bind neither TRAF2 nor TRAF3
still induces fluorescence greater than 1-231-A5 and 1-
187 mutants (Figure 3C). Whether the residual BiFC
with A5-Y384G is the result of specific or non-specific
interaction is unclear.
As BiFC can be induced anywhere in the cell, cells can
be observed for the localization of fluorescence by fluor-
escence microscopy. In contrast to fluorescence induced
with NYFP-CTAR1/2 and CYFP-TRAF combinations,
which was cytoplasmic, different combinations of full-
length LMP1 and TRAFs fused at either the amino- or
carboxyl-terminus to CYFP resulted in different patterns
of staining (Figure 4). The two patterns correlated with
the TRAF configuration and fluorescence. The TRAFs
tagged at their amino-termini with the CYFP domain,
which induced brigher fluorescence (Figure 2A, black
and white bars), had fluorescence in two regions of the
cell. As shown in the high magnification panel for
LMP1-NYFP + CYFP-TRAF3 (Figure 4A), there was
crescent-shaped bright fluorescence in a region that
appeared to be perinuclear (Figure 4A, white arrows).
Second, there were patches off l u o r e s c e n c ea tt h ep e r i -
meter of the cell that are likely plasma membrane asso-
ciated (Figure 4A, closed arrowheads). Both perinuclear
and membrane fluorescence is consistent with pre-
viously described localization of LMP1-signaling com-
plexes in LMP1-tranfected and EBV-infected cells
[51,52]. The second fluorescence pattern, that was
o b s e r v e dw i t ht h eT R A F st a g g e da tt h ec a r b o x y lt e r m i -
nus, which had lower MFI (Figure 2A, grey bars), was
localized in discrete foci within cytoplasmic compart-
ment, e.g. LMP1-NYFP + TRAF3-CYFP (Figure 4B,
open arrowheads). These data correlate the LMP1-NYFP
+ CYFP-TRAF combinations with the greatest fluores-
cence, that were decreased by CTAR mutation or dele-
tion, with previously described the membrane and
perinuclear fluorescence of LMP1 signaling complexes.
LMP1 + LMP1 BiFC
The membrane domain of LMP1 is able to self-associate
to induce signaling through the cytoplasmic domain of
LMP1. To determine if LMP1 + LMP1 binding induces
BiFC, assays were performed with LMP1 containing
both YFP domains as partners (Figure 5). LMP1-NYFP
+ LMP1-CYFP induced strong fluorescence and NYFP-
CTAR1/2 + 1-187-CYFP induced minimal fluorescence
(Figure 5A, blue and green histograms, respectively). As
with the LMP1-NYFP + CYFP-TRAF combinations,
LMP1-LMP1 BiFC was localized to the perinuclear and
plasma membranes of the cells (Figure 5B, white arrows
and arrowheads, respectively). Switching the configura-
tion of the YFP domains from the carboxyl to the
amino terminus of LMP1 in different combinations
resulted in lower levels of fluorescence complementation
as measured by the mean fluorescence intensity by flow
cytometry (data not shown). This suggests that LMP1-
NYFP + LMP1-CYFP are the combination that most
easily favors the assembly of YFP.
Activation of NF-B by BiFC Constructs
To assess the ability of LMP1 BiFC constructs to acti-
vate NF-B, promoter reporter assays were performed
with combinations of plasmids that induce BiFC. HEK-
293T cells were cotransfected with an NF-B promoter
reporter (pNF-B-Luc), transfection control Renilla luci-
ferase (pRL-SV40), and effector plasmids. Effector plas-
mids include vector control (DNA3), N-terminally myc-
tagged LMP1 (described previously [5], (LMP1)), LMP1-
NYFP + LMP1-CYFP (LMP1 BiFC), and A5-Y384G-
NYFP + A5-Y384G-CYFP (A5-Y384G BiFC). NF-B-
Luc promoter activity was plotted relative to the internal
control Renilla luciferase activity (Figure 5C). As
expected, LMP1 activates the NF-B reporter compared
to vector, approximately 45-fold. LMP1 BiFC plasmids
activate the NF-Br e p o r t e rt oas i m i l a re x t e n ta s
LMP1. In parallel cells were analyzed for BiFC by flow
cytometry (Figure 5D). LMP1 BiFC cells (blue histo-
gram) also induced BiFC while vector and LMP1 cells
had no YFP fluorescence as expected (red and green his-
tograms, respectively). This indicates that LMP1 com-
plexes which are inducing fluorescence are also
inducing NF-B signaling. A5-Y384G BiFC plasmids
also induced the NF-B reporter to about 50% of LMP1
and LMP1-BiFC NF-B activation, approximately 22-
fold above vector. This was unexpected as the A5-
Y384G mutant was previously described to be defective
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LMP1-NYFP + CYFP-TRAF3
A)
B)
Figure 4 Localization of LMP1 + TRAF BiFC. Cells were plated on coverslips and transfected with the indicated BiFC plasmids. Twenty-four
hours post-transfection cells were fixed, counterstained with DAPI, and mounted. High resolution images were acquired using a confocal
microscope. Individual colors, blue (DAPI), red (mCherry transfection control), green (BiFC), and merged images are displayed. Representative cells
(white boxes) were magnified and various fluorescence localizations are indicated: perinuclear (white arrows), membrane (white arrowheads), and
cytoplasmic (open arrowheads).
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Figure 5 LMP1 + LMP1 BiFC and NF-B Activity. Fluorescence complementation between the indicated LMP1 combinations was determined.
BiFC was determined by flow cytometry as described above (Figure 3). Representative YFP histograms of 1 × 10
4 mCherry positive cells for
LMP1-NYFP +LMP1-CYFP (blue), NYFP-CTAR1/2 + 1-187-CYFP (green), and mCherry alone (no BiFC plasmids, red) are displayed. Localization of
LMP1-NYFP +LMP1-CYFP BiFC (panel B) was determined as in Figure 4. Perinuclear (white arrows) and membrane (white arrowheads) BiFC is
indicated. Promoter reporter assays were performed by transfection of 293T cells with control pRL-SV40, pNF-B-luc, and vector (DNA3), LMP1,
LMP1-BiFC (LMP1-NYFP + LMP1-CYFP) or A5Y384G BiFC (A5-Y384G-NYFP + A5-Y384G-CYFP) plasmids. Forty hours post-transfection, cells were
harvested and dual-luciferase assays were performed. Relative luciferase activity was determined by the firefly luciferase activity of the NF-B
reporter construct relative to the control Renilla luciferase activity. Each combination was performed in triplicate and the mean relative NF-B
activity is displayed. Error bars represent the standard deviations from the mean and the experiment has been repeated three times. In parallel
BiFC was determined from the cells in the reporter assay (Panel D) as described above (Figure 3). Representative YFP histograms for DNA3 (red),
LMP1 (green), LMP1 BiFC (blue), and A5Y384G BiFC (purple) are displayed.
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LMP1 [46]. A5-Y384G BiFC plasmids also induce fluor-
escence (Figure 5D, purple histogram), which is
expected since LMP1-LMP1 binding is mediated by the
transmembrane domain. The fact that the A5-Y384G
BiFC plasmids induce activation of the NF-Br e p o r t e r
suggests that the unanticipated A5-Y384G + TRAF
BiFC (Figure 3A and 3B, orange histograms) is detecting
association between the TRAFs and the A5-Y384G
mutant that is inducing signaling. This also reinforces
the use of BiFC in detecting physiological interactions.
Transformation Assays with LMP1 BiFC Proteins
LMP1-TRAF and LMP1-LMP1 BiFC and LMP1-LMP1
NF-B activation suggests that activation of NF-Bi s
n o ti m p a i r e db yt h eN Y F Pa n dC Y F Pd o m a i n s .R o d e n t
fibroblast transformation requires both PI3K and ERK
signaling through CTAR1 [6,7]. To determine if LMP1-
NYFP is able to activate PI3K and ERK signaling, trans-
formation assays were performed. LMP1-NYFP was sub-
cloned into pBabe retrovirus expression vectors and
used in transformation assays (Figures 6, 7, and 8). Rat-
1 cells were infected with vector control, HA-tagged
LMP1, and LMP1-NYFP retrovirus. Infected cells were
selected with puromycin and examined after 5 days for
altered growth properties (Figure 6). Vector control cells
exhibited normal morphology and grew as a monolayer
on tissue culture plates (Figure 6A), but both LMP1 and
LMP1-NYFP expressing cells appeared spindly and grow
on top of each other in patches (Figure 6B and 6C,
respectively). In some areas the LMP1 cells grew in
tight clumps that were not observed in LMP-NYFP
cells, but LMP1-NYFP cells had an elongated morphol-
ogy consistent with phenotypic transformation. To
determine if LMP1-NYFP and 1-231-NYFP were able to
induce transformation, Rat-1 cells were transduced with
retrovirus and focus formation and soft agar assays were
performed. In focus formation assays control cells were
contact inhibited and stopped growing upon confluence
(Figure 7A), while both LMP1 and LMP1-NYFP induced
foci in Rat-1 cells (Figure 7B and 7C, respectively). Sta-
bly transduced cells were seeded into soft agar and
observed for anchorage independent growth (Figure 8).
Vector control cells did not grow in an anchorage inde-
pendent manner (Figure 8A). Both LMP1 and LMP1-
NYFP grew in an anchorage independent fashion and
formed colonies in soft agar (Figure 8B and 8C, respec-
tively. In parallel, stable cells were examined by western
blotting for LMP1 expression (data not shown). In our
previous studies LMP1 mutants containing amino acids
1-231 were sufficient to induce transformation [6,7] and
1-231-NYFP expressing retrovirus also induced focus
formation in monolayers and colony formation in soft
agar (data not shown). These data indicate that the
presence of the YFP domain at the carboxyl-terminus of
LMP1 does not impair LMP1 signaling through PI3K
and ERK that are required for rodent fibroblast
transformation.
Discussion
The data presented in this study utilize the in vivo tech-
nique of BiFC to study assembly of LMP1 signaling
complexes within cells. Fluorescence complementation
was observed with LMP1 and TRAF2 or TRAF3. Muta-
tion of CTAR1 and/or CTAR2 decreased fluorescence
of LMP1 + TRAF combinations. LMP1 + LMP1 com-
plementation was also observed. Both LMP1 + TRAF
and LMP1 + LMP1 BiFC localized to perinuclear and
membrane which is consistent with previously described
LMP-signaling complexes. LMP1 mutants containing
only the signaling domain of LMP1 induced cytoplasmic
fluorescence with the TRAFs. LMP1 fusion proteins
containing the YFP domain at the carboxyl-terminus of
A)
B) LMP1
C)
Vector
LMP1-NYFP
Figure 6 Phenotype of LMP1-NYFP Stables.L M P 1 - N Y F Pw a s
subcloned into the pBabe packaging retrovirus. Control (Vector),
LMP1, and LMP1-NYFP retrovirus were produced in HEK-293T cells.
Rat-1 cells (rodent fibroblasts) were infected with the indicated
retroviruses. Stable cell were selected and examined for phenotypic
transformation. Subconfluent stable cells were fixed and stained
with crystal violet. Representative micrographs taken with a
dissecting microscope are presented.
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mation of Rat-1 cells.
The data presented here reinforce the utility of using
BiFC to study protein-protein interactions. However,
several cautions are also highlighted by our studies.
First, overexpression of proteins must be avoided.
Transfection of ten-fold less plasmids resulted in dimin-
ished non-specific BiFC (Figure 3). Second, in the
absence of structural information, different combina-
tions and orientations of YFP domains on binding part-
ners should be screened to find optimal BiFC partners
to minimize steric hinderance. Third, correct cellular
localization or mutations in known binding domains
should be employed to ensure observed BiFC is physio-
logically relevant. BiFC between LMP1-NYFP and
CYFP-TRAF2 or CYFP-TRAF3 was observed in physio-
logical locations, perinuclear and membrane associated,
and diminished by CTAR1 and CTAR2 mutation. In
contrast, BiFC between LMP1-NYFP and TRAF2-CYFP
or TRAF3-CYFP was observed in an unknown
cytoplasmic compartment and was not diminished by
CTAR1 and CTAR2 mutations. This indicates that
TRAF-CYFP combinations will not yield insight into
LMP1 binding and signaling. Last, it is important to
ensure that the presence of the YFP domain does not
affect critical properties of the protein. LMP1 BiFC pro-
teins were able to activate NF-B and induce rodent
fibroblast transformation.
LMP1-binding proteins were initially identified using
Y2H screens with the cytoplasmic domain of LMP1
[48]. Although Y2H screens are powerful tools for iden-
tifying and characterizing protein-protein interactions,
Y2H requires interacting proteins to be transported to
the nucleus to induce transcription of reporter genes
which generally precludes the inclusion of transmem-
brane domains. LMP1 signaling occurs in the choles-
terol rich lipid raft domains of the membrane [20-26].
The contribution of the membrane domain of LMP1 to
recruitment of downstream effector proteins can gener-
ally not be determined by Y2H. In contrast, bimolecular
fluorescence complementation does not require nuclear
localization and can be performed within mammalian
cells. Previous immunofluorescence for LMP1 or tagging
of LMP1 with green or red fluorescent proteins resulted
in fluorescence in membrane patches as well as fluores-
cence in perinuclear regions of the cell (e.g. [51,52]).
BiFC with both LMP1 + TRAF and LMP1 + LMP1
A)
B) LMP1
C)
Vector
LMP1-NYFP
Figure 7 Focus Formation with LMP1-NYFP. Rat-1 monolayers
were infected with Vector, LMP1, and LMP1-NYFP retrovirus and
focus formation assays for contact-inhibition were performed. Ten
days post-infection cells were fixed and stained with crystal violet
for foci. Representative micrographs taken with a dissecting
microscope are presented.
A)
B) LMP1
C)
Vector
LMP1-NYFP
Figure 8 Anchorage Independent Growth with LMP1-NYFP. Rat-
1 cells were infected with Vector, LMP1, and LMP1-NYFP retrovirus
and stable cells were selected. Stable cells were analyzed for
anchorage-independent growth in soft agar for 10 days and stained
with MTT. Representative micrographs taken with a dissecting
microscope are presented.
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and perinuclear fluorescence as well. This suggests that
the fluorescence resulting from BiFC is induced by
LMP1 signaling complexes within a physiological con-
text and demonstrates the utility of BiFC to study the
assembly of LMP1-signaling complexes in membrane of
mammalian cells.
The CTAR2 signaling domain has been defined as the
terminal three amino acids YYD of LMP1. There was
concern that addition of the YFP domain to C-terminus
might inhibit CTAR2 signaling. However, several of our
experiments suggest that this is not the case. First, dele-
tion of CTAR2, LMP1-NYFP to 1-231-NYFP, resulted
in a decrease in BiFC with CYFP-TRAF2 which can
bind to either CTAR1 or CTAR2. Second, the majority
of the NF-B activation is a result of CTAR2 [16] and
LMP1 BiFC plasmids were as effective as LMP1 in
induction of the NF-B reporter. Our studies suggest
that the presence of the NYFP domain functions as a
suppressor for the Y384G mutation or act as a gain of
function for CTAR2 signaling. Although we were con-
cerned that CYFP-TRAF2 binding to A5-Y384G-NYFP
was an artifact. The NF-B reporter activation suggests
that TRAF2 is binding to A5-Y384G-NYFP to induce
signaling. The fusion protein junction may create a new
or secondary CTAR2 sequence. Mutation of CTAR2
from wild-type (YYD) to GYD at the C-terminus of
LMP1 abrogates CTAR2 signaling. A5-Y384G-NYFP
creates the sequence GYDIDGGGGSGGGGS at the
junction between LMP1 and NYFP, where the GYD is
the mutated CTAR2, ID is contributed by a restriction
enzyme site, and GGGGSGGGGS is the linker sequence
of the BiFC vector. Our hypothesis is that Y385 and
D388 in the junction sequence are able to substitute for
Y384 and D386 in the wild-type CTAR2. In any case,
this new TRAF2 binding to A5-Y384G-NYFP was
detected by BiFC and its function was confirmed by the
NF-B reporter activation.
Several recently developed techniques have been
developed to not only characterize known protein-pro-
tein interactions but screen for new interacting partners
via BiFC [53-56]. LMP1-NYFP could be used as a bait
protein to screen an expression library cloned down-
stream of CYFP. Fluorescent cells can be identified and
isolated using fluorescence activated cell sorting and the
interacting genes can be identified by reverse genetics.
Performing such a screen in mammalian cells could
have several advantages over a technique like Y2H.
Since these screens are performed in mammalian cells,
all physiologically relevant accessory proteins would also
be present. Because of the flexible linker region, it may
also be possible to identify indirect targets of LMP-
mediated signaling, i.e. downstream proteins recruited
to LMP1 by the TRAFs which might not directly bind
LMP1. As described above, our BiFC data suggest that
TRAF2 binding to CTAR2, which is an indirect binding,
is intact. As the association of the YFP domains in BiFC
is considered to be nearly irreversible, it may be possible
to capture low-affinity or transient interactions as well
[44]. BiFC may be valuable tool to characterize the pro-
teins recruited to LMP1 within the context of the
dynamic signaling environment.
Fluorescence based assays are powerful tools to exam-
ine protein-protein interactions. Since LMP1 + TRAF
a n dL M P 1+L M P 1a s s o c i a t i o nw e r ea b l et ob ev i s u a -
lized by BiFC, it suggests that the LMP1 signaling com-
p l e xc o u l da l s ob ep r o b e du s i n gam o r er i g o r o u s
fluorescence techniques like fluorescence resonance
energy transfer (FRET). FRET requires that donor and
acceptor proteins are within 10 nm of each other. BiFC
combinations that result in high fluorescence represent
likely combinations for positions for FRET partners.
Dynamic interactions could be rigorously examined
using an approach such as FRET. Recently a technique
that uses a combination of BiFC and FRET to study the
assembly of ternary complex of transcription factors in
real-time within the nucleus of the cells has been
described [57-59]. Such approaches could be applied to
the assembly of signaling complexes. As new proteins
recruited to the LMP1-signaling complex are identified,
the assembly of the LMP1-signaling complex in real-
time in the membrane of cells could be determined.
Furthermore, fluorescence-based binding assays could
be used to screen compound libraries for inhibitors of
LMP1 signaling.
Conclusions
Together these data indicate that BiFC serves as a novel
in vivo platform to study LMP1 signaling in the mem-
brane of mammalian cells, including NF-B, PI3K and
ERK signaling.
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